Health Care Technology
Company Overview of Proteus Digital Health, Inc.
Proteus Digital Health, Inc. operates as a digital medicines company. The company focuses on developing products, services, and data systems based on integrating medicines with ingestible, wearable, mobile, and cloud computing. Its digital health feedback technology provides a view into an individual’s personal health choices and physiologic response, allowing patients to manage their health, and collaborate with caregivers and clinicians. Proteus Digital Health, Inc. was formerly known as Proteus Biomedical, Inc. and changed its name to Proteus Digital Health, Inc. in July 2012. Proteus Digital Health, Inc. was founded in 2001 and is headquartered in Redwood City, California. As of February...
2600 Bridge Parkway
Redwood City, CA 94065
Founded in 2001
Key Executives for Proteus Digital Health, Inc.
Co-Founder, Chief Executive Officer and President
Co-Founder and Chief Technologist
Co-Founder and Chief Medical Officer
Compensation as of Fiscal Year 2017.
Proteus Digital Health, Inc. Key Developments
Proteus Digital Health And Proteus Digital Health Announces First U.S. FDA Approval Of A Digital Medicine System
Nov 14 17
Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health announced that the United States Food and Drug Administration has granted the first approval of a digital medicine system, ABILIFY MYCITE (aripiprazole tablets with sensor), a drug-device combination product comprised of Otsuka's oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. The ABILIFY MYCITE System includes: ABILIFY MYCITE, the MYCITE Patch (a wearable sensor, developed by Proteus); the MYCITE APP, a smartphone application (app), used with a compatible smartphone to display information for the patient; and web-based portals for healthcare providers and caregivers that display a summary of aripiprazole ingestion over time. Only functions of the app related to tracking drug ingestion have been approved by the FDA. ABILIFY MYCITE, an atypical antipsychotic, is indicated in adults for the treatment of schizophrenia, for the treatment of acute manic and mixed episodes, and maintenance treatment of bipolar I disorder as monotherapy, and as adjunctive therapy to lithium or valproate, and the adjunctive treatment of major depressive disorder.1 ABILIFY MYCITE is intended to track drug ingestion. The ability of ABILIFY MYCITE to improve patient compliance or modify aripiprazole dosage has not been established. The use of ABILIFY MYCITE to track drug ingestion in "real-time" or during an emergency is not recommended because detection may be delayed or not occur. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death (1.6 to 1.7 times) compared to placebo-treated patients. ABILIFY MYCITE is not approved for the treatment of patients with dementia-related psychosis. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults. Those on antidepressant therapy should be monitored closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. ABILIFY MYCITE is not approved for use in pediatric patients.
Proteus Digital Health Appoints Regina Benjamin to its Board of Directors
Sep 5 17
Proteus Digital Health™ announced the addition of Regina Benjamin, MD, MBA, the 18th United States Surgeon General, to its Board of Directors.
As America’s Doctor from July 2009 to 2013, Dr. Benjamin provided the public with the best scientific information available on how to improve their health and the health of the nation. Dr. Benjamin is Founder and CEO of BayouClinic in rural Alabama, and holds the NOLA.com/The Times Picayune Endowed Chair in Public Health Sciences at Xavier University of Louisiana.
Proteus Digital Health Appoints Uneek Mehra as Chief Financial Officer
Aug 23 17
Proteus Digital Health™ announced that Uneek Mehra has joined the company as Chief Financial Officer. Mr. Mehra has more than twenty years of global finance experience and was previously a senior leader in finance at Novartis. As Chief Financial Officer Mr. Mehra will lead the Finance, IT, People and Facilities teams. He will be a key driver of growth as Proteus expands its commercial footprint in the US and Asia, both directly and through partnerships with pharmaceutical companies. Mr. Mehra has deep experience across pharmaceuticals, technology and financial services, through senior roles at Novartis, IBM and Citibank. At Novartis, he had responsibilities in Corporate Finance, Commercial Finance, Corporate Business Development and Treasury across the US, Switzerland and China.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|